accountBy Frankfurt Bureau FRANKFURT (MarketWatch) -- German pharmaceutical company Bayer AG (BAYN.XE) said Wednesday its oral anti-clotting drug rivaroxaban has shown a positive benefit-risk profile in certain patients, following a secondary prevention...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Bayer: Rivaroxaban effective in stroke prevention
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account